Cargando…
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
SIMPLE SUMMARY: Monoclonal antibodies represent a major therapeutic progress in multiple myeloma during the last decade. The use of antibodies as well as antibody drug conjugates has changed the treatment landscape rapidly. The intent of this paper is to summarize the current major results of monocl...
Autores principales: | Radocha, Jakub, van de Donk, Niels W. C. J., Weisel, Katja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037134/ https://www.ncbi.nlm.nih.gov/pubmed/33805481 http://dx.doi.org/10.3390/cancers13071571 |
Ejemplares similares
-
T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
por: O'Neill, Chloe, et al.
Publicado: (2023) -
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022) -
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018) -
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
por: Abramson, Hanley N.
Publicado: (2018) -
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)